Partner Headlines - EXEL

  1. Benzinga's Top #PreMarket Losers

    Benzinga
  2. Watch These 10 Stocks Over The Weekend

    Benzinga
  3. Morning Market Gainers

    Benzinga
  4. Benzinga's Top #PreMarket Gainers

    Benzinga
  5. Morning Market Gainers

    Benzinga
  6. Benzinga's Top #PreMarket Gainers

    Benzinga
  7. Exelixis Data Release Upcoming; Options Activity Spiking

    Benzinga
  8. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  9. 5-year lows: Synta Pharmaceuticals Inc, Exelixis Inc, Entropic ...

    GuruFocus
  10. Mid-Day Market Update: ON Semiconductor Surges On $1 Billion ...

    Benzinga
  11. Mid-Morning Market Update: Markets Open Lower; Weatherford To ...

    Benzinga
  12. Morning Market Losers

    Benzinga
  13. Events for the Week of Nov. 17-21, 2014

    Benzinga
  14. Morning Market Movers

    Benzinga
  15. 5-year lows: National Presto Industries, Ennis Inc, Landauer ...

    GuruFocus
  16. Stocks Hitting 52-Week Lows

    Benzinga
  17. Equities, Commodities & Bonds Finish Lower On First Trading Day ...

    Benzinga
  18. Midday Losers From Tuesday, September 2

    Benzinga
  19. Exelixis Shares Slide On Trial Results; Norwegian Cruise Line ...

    Benzinga
  20. Markets Mixed; Conn's Profit Misses Estimates

    Benzinga
  21. Stocks Hitting 52-Week Lows

    Benzinga
  22. Morning Market Losers

    Benzinga
  23. Benzinga's Top Downgrades

    Benzinga
  24. Stifel Nicolaus Downgrades Exelixis To Hold

    Benzinga
  25. Stocks To Watch For September 2, 2014

    Benzinga
  26. Exelixis Announces Results From COMET-1 Phase 3 Pivotal Trial ...

    Benzinga
  27. Mid-Afternoon Market Update: Harmonic Drops On Weak Forecast; ...

    Benzinga
  28. Harmonic Drops On Weak Forecast; URS Shares Surge

    Benzinga
  29. Mid-Morning Market Update: Markets Open Higher; Citigroup Profit ...

    Benzinga
  30. Morning Market Movers

    Benzinga
  31. Exelixis Shares Move 12% On Phase 3 Data

    Benzinga
  32. Benzinga's Top #PreMarket Gainers

    Benzinga
  33. Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th

    Benzinga
  34. Benzinga's Top #PreMarket Gainers

    Benzinga
  35. Five-Year Lows: Rentech Nitrogen Partners LP, SandRidge Permian ...

    GuruFocus
  36. Market Wrap For March 26: Markets Close Near Session Lows In ...

    Benzinga
  37. Mid-Afternoon Market Update: Markets Turn Red as Dish Network ...

    Benzinga
  38. Mid-Day Market Update: Five Below Jumps On Upbeat Results; Exelixis ...

    Benzinga
  39. Mid-Morning Market Update: Markets Open Higher; Francesca's Issues ...

    Benzinga
  40. Stocks Hitting 52-Week Lows

    Benzinga
  41. Morning Market Losers

    Benzinga
  42. Benzinga's Top #PreMarket Losers

    Benzinga
  43. Morning Market Movers

    Benzinga
  44. US Stock Futures Rise Ahead Of Housing Data

    Benzinga
  45. Exelixis Prices 10M Share Offering at $8 per Share

    Benzinga
  46. Oversold ETFs Looking Attractive (IHE, CSD, PSCE)

    Benzinga
  47. Exelixis Announces Promising Phase 1b Data for Cobimetinib in ...

    Benzinga
  48. US Stock Futures Rise Ahead Of Jobless Claims, GDP Data

    Benzinga
  49. Exelixis Announces Full Patient Enrollment for COMET-1 Phase ...

    Benzinga
  50. US Stock Futures Up After Upbeat China Data

    Benzinga
  51. Exelixis Initiates Phase 3 Clinical Trial of Cabozantinib

    Benzinga
  52. Exelixis Receives EMA Acceptance of Marketing Authorization App ...

    Benzinga
  53. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  54. Exel Presents Interim Data for Cabozantinib 40 mg Dose Cohort ...

    Benzinga
  55. First Solar, Sears Holdings Among Stocks Down on Above-average ...

    FoxBusiness
  56. Exelixis Says FDA Says NDA Has Been Removed from November Agenda

    Benzinga
  57. UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity ...

    Benzinga
  58. Social Media Outlook for Thursday August 9 (EAT, NOV, NWSA, FSYS)

    Benzinga
  59. Exelixis, Universal Display Corporation Among Stocks Up on High ...

    FoxBusiness
  60. FDA's Oncologic Drugs Advisory Committee to Review Exelixis New ...

    Benzinga
  61. Exelixis (EXEL) Loses 8.8% As Company Sells Stock, Debt

    MarketIntelligenceCenter
  62. Health Care Sector Wrap

    FoxBusiness
  63. HCA Holdings, American Capital Mortgage Investment Crp Among ...

    FoxBusiness
  64. Interpublic Group, Exelixis Gapping Down Monday

    FoxBusiness
  65. UPDATE: Exelixis Announces Proposed Convertible Debt Offering ...

    Benzinga
  66. Exelixis Proposed Offering 20M Shares

    Benzinga
  67. Exelixis Inc. Reports Operating Results (10-Q)

    GuruFocus
  68. Social Media Outlook for Monday July 30 (SHAW, BBY, EXEL, VHC)

    Benzinga
  69. Benzinga's Top Pre-Market Gainers

    Benzinga
  70. FDA Grants Priority Review for Cabozantinib in Medullary Thyroid ...

    Benzinga
  71. Exelixis Announces Initiation of Cabozantinib Investigator-Sponsored ...

    Benzinga
  72. Jefferies Reiterates Hold Rating, $6 PT for Exelixis

    Benzinga
  73. Cabozantinib Demonstrates Durable Effects in Bone and Soft Tissue ...

    Benzinga
  74. Cabozantinib Meets Primary Endpoint of Progression Free Survival ...

    Benzinga
  75. Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily ...

    Benzinga
  76. Exelixis Completes Submission of New Drug Application for Cabozantinib ...

    Benzinga
  77. Exelixis Initiates COMET-1 Pivotal Trial Focused on Overall Survival ...

    Benzinga
  78. Exelixis Expands the Cabozantinib Development Program Through ...

    Benzinga
  79. Exelixis Announces Initiation of Investigator-Sponsored Clinical ...

    Benzinga
  80. 5 Resilient Biotech Stocks to Buy for 2012

    GuruFocus
  81. Top 4 NASDAQ Stocks In The Biotechnology Industry With The Lowest ...

    Benzinga
  82. Exelixis (EXEL) Gains 2.8% After Pricing 11 Million Share Offering ...

    MarketIntelligenceCenter
  83. Exelixis Announces Pricing of $60.5 Million Public Offering at ...

    Benzinga
  84. Exelixis Announces Proposed Public Offering of 10M Shares

    Benzinga
  85. Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data ...

    Benzinga
  86. Notable Call Options Activity on Exelixis

    Benzinga
  87. Exelixis Trading Higher After Licensing Agreement with Merck

    Benzinga
  88. Exelixis Lures Premium Sellers on Positive Drug Data

    SchaeffersResearch
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!